Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy

Double-blind Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Allogenic Umbilical Cord Blood and Erythropoietin for Children With Cerebral Palsy

This randomized control study is aimed to determine efficacy of umbilical cord blood and erythropoietin combination therapy for children with cerebral palsy.

Cerebral palsy is a disorder of movement and posture that result from a nonprogressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability through one's life. Umbilical cord blood(UCB) is suggested as therapeutic method for cerebral palsy which resulted from animal studies. Stem cells included in UCB is expected to exert therapeutic efficacy for functional recovery.

It is also suggested that erythropoietin is useful to repair neurological injury in brain. The main mechanism of erythropoietin is supposed to be neuroprotection and neurogenesis which would reinforce the effect of stem cell as well.

Although autologous umbilical cord would be safe, the children who have problems at birth seldom have autologous umbilical cord blood. Allogenic umbilical cord blood might be useful for these children if its effect is approved.

Inclusion Criteria:

• Known cerebral palsy
• Willing to comply with all study procedure

Exclusion Criteria:

• High risk of pneumonia or renal function deterioration after using of immunosuppressant
• Presence of known genetic disease
• Possibility of drug hypersensitivity which is related to this study remedy
• History of previous cell therapy
• Poor cooperation of guardian,including inactive attitude for rehabilitation
• Intractable seizure disorder
• Autism